BOT – Botanix Pharmaceuticals Ltd


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Botanix Pharmaceuticals Limited is an Australia-based dermatology-focused company. The Company is engaged in the development of novel treatments for common skin diseases and infections. The Company has two development platforms, dermatology and antimicrobial products, both of which leverage the anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids. The Company’s product pipeline consists of Sofpironium Bromide, BTX 1503, BTX 1702, BTX 1204A, and BTX 1801. Sofpironium Bromide is an anticholinergic/antimuscarinic drug that blocks sweating at the gland by binding to the receptor and thereby blocking the sweat signal. Its BTX1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 is used for the treatment of papulopustular rosacea. Its BTX 1204A is used for Atopic Dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan